MILAN, May 13, 2024--Newron reports new data from pivotal study 008A for chronic schizophrenia patients revealing clinically significant efficacy benefits over time.
MILAN, April 30, 2024--Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
MILAN, April 08, 2024--Newron presents existing evenamide study 014/015 data and future clinical development outlook for evenamide at 2024 SIRS Congress in Florence, Italy